416 related articles for article (PubMed ID: 31359615)
41. Multilevel predictors of concurrent opioid use during methadone maintenance treatment among drug users with HIV/AIDS.
Tran BX; Ohinmaa A; Mills S; Duong AT; Nguyen LT; Jacobs P; Houston S
PLoS One; 2012; 7(12):e51569. PubMed ID: 23251580
[TBL] [Abstract][Full Text] [Related]
42. Relationship between hunger, adherence to antiretroviral therapy and plasma HIV RNA suppression among HIV-positive illicit drug users in a Canadian setting.
Anema A; Kerr T; Milloy MJ; Feng C; Montaner JS; Wood E
AIDS Care; 2014 Apr; 26(4):459-65. PubMed ID: 24015838
[TBL] [Abstract][Full Text] [Related]
43. Factors associated with discontinuation of methadone maintenance therapy (MMT) among persons who use alcohol in Vancouver, Canada.
Klimas J; Nosova E; Socías E; Nolan S; Brar R; Hayashi K; Milloy MJ; Kerr T; Wood E
Drug Alcohol Depend; 2018 May; 186():182-186. PubMed ID: 29604525
[TBL] [Abstract][Full Text] [Related]
44. Psychosocial factors in adherence to antiretroviral therapy among HIV-positive people who use drugs.
Lee WK; Milloy MJ; Walsh J; Nguyen P; Wood E; Kerr T
Health Psychol; 2016 Mar; 35(3):290-7. PubMed ID: 26690643
[TBL] [Abstract][Full Text] [Related]
45. Homelessness as a structural barrier to effective antiretroviral therapy among HIV-seropositive illicit drug users in a Canadian setting.
Milloy MJ; Kerr T; Bangsberg DR; Buxton J; Parashar S; Guillemi S; Montaner J; Wood E
AIDS Patient Care STDS; 2012 Jan; 26(1):60-7. PubMed ID: 22107040
[TBL] [Abstract][Full Text] [Related]
46. Impact of Opioid Substitution Therapy on Antiretroviral Therapy Outcomes: A Systematic Review and Meta-Analysis.
Low AJ; Mburu G; Welton NJ; May MT; Davies CF; French C; Turner KM; Looker KJ; Christensen H; McLean S; Rhodes T; Platt L; Hickman M; Guise A; Vickerman P
Clin Infect Dis; 2016 Oct; 63(8):1094-1104. PubMed ID: 27343545
[TBL] [Abstract][Full Text] [Related]
47. Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users.
Milloy MJ; Kerr T; Buxton J; Rhodes T; Guillemi S; Hogg R; Montaner J; Wood E
J Infect Dis; 2011 May; 203(9):1215-21. PubMed ID: 21459814
[TBL] [Abstract][Full Text] [Related]
48. Plasma HIV-1 RNA viral load rebound among people who inject drugs receiving antiretroviral therapy (ART) in a Canadian setting: an ethno-epidemiological study.
Small W; Milloy MJ; McNeil R; Maher L; Kerr T
AIDS Res Ther; 2016; 13():26. PubMed ID: 27462360
[TBL] [Abstract][Full Text] [Related]
49. Impact of methadone maintenance on health utility, health care utilization and expenditure in drug users with HIV/AIDS.
Tran BX; Nguyen LT
Int J Drug Policy; 2013 Nov; 24(6):e105-10. PubMed ID: 23937854
[TBL] [Abstract][Full Text] [Related]
50. Barriers to retention in methadone maintenance therapy among people who inject drugs in Bangkok, Thailand: a mixed-methods study.
Hayashi K; Ti L; Ayutthaya PPN; Suwannawong P; Kaplan K; Small W; Kerr T
Harm Reduct J; 2017 Sep; 14(1):63. PubMed ID: 28882155
[TBL] [Abstract][Full Text] [Related]
51. Socioeconomic marginalization and plasma HIV-1 RNA nondetectability among individuals who use illicit drugs in a Canadian setting.
Richardson LA; Kerr TH; Dobrer S; Puskas CM; Guillemi SA; Montaner JS; Wood E; Milloy MJ
AIDS; 2015 Nov; 29(18):2487-95. PubMed ID: 26558546
[TBL] [Abstract][Full Text] [Related]
52. Pain Among High-Risk Patients on Methadone Maintenance Treatment.
Voon P; Hayashi K; Milloy MJ; Nguyen P; Wood E; Montaner J; Kerr T
J Pain; 2015 Sep; 16(9):887-94. PubMed ID: 26101814
[TBL] [Abstract][Full Text] [Related]
53. Influence of noninjecting and injecting drug use on mortality, retention in the cohort, and antiretroviral therapy, in participants in the Swiss HIV Cohort Study.
Weber R; Huber M; Battegay M; Stähelin C; Castro Batanjer E; Calmy A; Bregenzer A; Bernasconi E; Schoeni-Affolter F; Ledergerber B;
HIV Med; 2015 Mar; 16(3):137-51. PubMed ID: 25124393
[TBL] [Abstract][Full Text] [Related]
54. The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users.
Nolan S; Dias Lima V; Fairbairn N; Kerr T; Montaner J; Grebely J; Wood E
Addiction; 2014 Dec; 109(12):2053-9. PubMed ID: 25041346
[TBL] [Abstract][Full Text] [Related]
55. Antiretroviral Therapy Interruption Among HIV Postive People Who Use Drugs in a Setting with a Community-Wide HIV Treatment-as-Prevention Initiative.
McNeil R; Kerr T; Coleman B; Maher L; Milloy MJ; Small W
AIDS Behav; 2017 Feb; 21(2):402-409. PubMed ID: 27351192
[TBL] [Abstract][Full Text] [Related]
56. Adherence and plasma HIV RNA response to antiretroviral therapy among HIV-seropositive injection drug users in a Canadian setting.
Nolan S; Milloy MJ; Zhang R; Kerr T; Hogg RS; Montaner JS; Wood E
AIDS Care; 2011 Aug; 23(8):980-7. PubMed ID: 21480010
[TBL] [Abstract][Full Text] [Related]
57. Impact of adherence counseling dose on antiretroviral adherence and HIV viral load among HIV-infected methadone maintained drug users.
Cooperman NA; Heo M; Berg KM; Li X; Litwin AH; Nahvi S; Arnsten JH
AIDS Care; 2012; 24(7):828-35. PubMed ID: 22272732
[TBL] [Abstract][Full Text] [Related]
58. Rationale, design, and sample characteristics of a randomized controlled trial of directly observed antiretroviral therapy delivered in methadone clinics.
Berg KM; Mouriz J; Li X; Duggan E; Goldberg U; Arnsten JH
Contemp Clin Trials; 2009 Sep; 30(5):481-9. PubMed ID: 19505589
[TBL] [Abstract][Full Text] [Related]
59. Factors associated with mortality of HIV-positive clients receiving methadone maintenance treatment in China.
Liu E; Rou K; McGoogan JM; Pang L; Cao X; Wang C; Luo W; Sullivan SG; Montaner JS; Bulterys M; Detels R; Wu Z;
J Infect Dis; 2013 Aug; 208(3):442-53. PubMed ID: 23592864
[TBL] [Abstract][Full Text] [Related]
60. A qualitative investigation of HIV treatment dispensing models and impacts on adherence among people living with HIV who use drugs.
Fleming T; Collins AB; Bardwell G; Fowler A; Boyd J; Milloy MJ; Small W; McNeil R
PLoS One; 2021; 16(2):e0246999. PubMed ID: 33635886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
